@article{e1a1338cf0a9475a91710d8a59f0e618,
title = "A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography: Journal of Cardiovascular Computed Tomography",
abstract = "Introduction: Non-statin therapy (NST)is used as second-line treatment when statin monotherapy is inadequate or poorly tolerated. Objective: To determine the association of NST with plaque composition, alone or in combination with statins, in patients undergoing coronary computed tomography angiography (coronary CTA). Methods: From the multicenter CONFIRM registry, we analyzed individuals who underwent coronary CTA with known lipid-lowering therapy status and without prior coronary artery disease at baseline. We created a propensity score for being on NST, followed by stepwise multivariate linear regression, adjusting for the propensity score as well as risk factors, to determine the association between NST and the number of coronary artery segments with each plaque type (non-calcified (NCP), partially calcified (PCP)or calcified (CP))and segment stenosis score (SSS). Results: Of the 27,125 subjects in CONFIRM, 4,945 met the inclusion criteria; 371 (7.5%)took NST. At baseline, patients on NST had more prevalent risk factors and were more likely to be on concomitant cardiac medications. After multivariate and propensity score adjustment, NST was not associated with plaque composition: NCP (0.07 increase, 95% CI: −0.05, 0.20; p = 0.26), PCP (0.10 increase, 95% CI: −0.10, 0.31; p = 0.33), CP (0.18 increase, 95% CI: −0.10, 0.46; p = 0.21)or SSS (0.45 increase, 95% CI: −0.02,0.93; p = 0.06). The absence of an effect of NST on plaque type was not modified by statin use (p for interaction > 0.05 for all). Conclusion: In this cross-sectional study, non-statin therapy was not associated with differences in plaque composition as assessed by coronary CTA. {\textcopyright} 2019",
keywords = "Coronary computed tomography angiography, Coronary plaque composition, Ezetimibe, Fibrate, Niacin, Non-statin therapy, antilipemic agent, biological marker, hydroxymethylglutaryl coenzyme A reductase inhibitor, lipid, adult, Article, computed tomographic angiography, coronary angiography, coronary artery atherosclerosis, coronary artery calcium score, coronary risk, cross-sectional study, female, human, major clinical study, male, middle aged, priority journal, propensity score, aged, Asia, atherosclerotic plaque, blood, clinical trial, combination drug therapy, coronary artery disease, coronary artery obstruction, coronary blood vessel, diagnostic imaging, dyslipidemia, Europe, multicenter study, North America, pathology, predictive value, prevalence, procedures, register, risk factor, Aged, Biomarkers, Computed Tomography Angiography, Coronary Angiography, Coronary Artery Disease, Coronary Stenosis, Coronary Vessels, Cross-Sectional Studies, Drug Therapy, Combination, Dyslipidemias, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Lipids, Male, Middle Aged, Plaque, Atherosclerotic, Predictive Value of Tests, Prevalence, Registries, Risk Factors",
author = "S.J. Al'Aref and A. Su and H. Gransar and {van Rosendael}, A.R. and A. Rizvi and D.S. Berman and T.Q. Callister and A. DeLago and M. Hadamitzky and J. Hausleiter and M.H. Al-Mallah and M.J. Budoff and P.A. Kaufmann and G.L. Raff and K. Chinnaiyan and F. Cademartiri and E. Maffei and T.C. Villines and Y.-J. Kim and J. Leipsic and G. Feuchtner and G. Pontone and D. Andreini and H. Marques and {de Ara{\'u}jo Gon{\c c}alves}, P. and R. Rubinshtein and S. Achenbach and H.-J. Chang and B.J.W. Chow and R. Cury and Y. Lu and J.J. Bax and E.C. Jones and J.M. Pe{\~n}a and L.J. Shaw and J.K. Min and F.Y. Lin",
note = "Cited By :1 Export Date: 5 February 2020 Correspondence Address: Lin, F.Y.; Weill Cornell Medicine and the Dalio Institute of Cardiovascular Imaging 413 E. 69th Street, Suite 108, United States; email: fal9003@med.cornell.edu Chemicals/CAS: lipid, 66455-18-3; Biomarkers; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids Funding details: National Institutes of Health Funding details: Dalio Foundation Funding details: GE Healthcare Funding details: Michael Wolk Heart Foundation Funding details: Foundation for the National Institutes of Health, R01 HL115150 Funding text 1: Dr. James K. Min receives funding from the Dalio Foundation, National Institutes of Health, and GE Healthcare, serves on the scientific advisory board of Arineta and GE Healthcare, and has an equity interest in Cleerly. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding text 2: The research reported in this publication was funded, in part, by the National Institute of Health (Bethesda, MD, USA) under award number R01 HL115150 . This research was also supported, in part, by the Dalio Institute of Cardiovascular Imaging (New York, NY, USA) and the Michael Wolk Foundation (New York, NY, USA). Appendix A References: Lloyd-Jones, D.M., Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on expert consensus decision pathways (2017) J Am Coll Cardiol, 70 (14), pp. 1785-1822. , 2017; MRC/BHF, Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial (2002) Lancet, 360 (9326), pp. 7-22; Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (1994) Lancet, 344 (8934), pp. 1383-1389; Ridker, P.M., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (2008) N Engl J Med, 359 (21), pp. 2195-2207; Sever, P.S., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial (2003) Lancet, 361 (9364), pp. 1149-1158; Cannon, C.P., Ezetimibe added to statin therapy after acute coronary syndromes (2015) N Engl J Med, 372 (25), pp. 2387-2397; Zeb, I., Effect of statin treatment on coronary plaque progression - a serial coronary CT angiography study (2013) Atherosclerosis, 231 (2), pp. 198-204; Li, Z., Effects of statin therapy on progression of mild noncalcified coronary plaque assessed by serial coronary computed tomography angiography: a multicenter prospective study (2016) Am Heart J, 180, pp. 29-38; Park, S.J., Effect of statin treatment on modifying plaque composition: a double-blind, randomized study (2016) J Am Coll Cardiol, 67 (15), pp. 1772-1783; Nakazato, R., Statins use and coronary artery plaque composition: results from the International Multicenter CONFIRM Registry (2012) Atherosclerosis, 225 (1), pp. 148-153; Puri, R., Impact of statins on serial coronary calcification during atheroma progression and regression (2015) J Am Coll Cardiol, 65 (13), pp. 1273-1282; Min, J.K., Rationale and design of the CONFIRM (COronary CT angiography EvaluatioN for clinical outcomes: an InteRnational multicenter)registry (2011) J Cardiovasc Comput Tomogr, 5 (2), pp. 84-92; Stone, N.J., ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2013) J Am Coll Cardiol, 63 (25), pp. 2889-2934. , 2014; Min, J.K., Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality (2007) J Am Coll Cardiol, 50 (12), pp. 1161-1170; Rubin, D.B., Using propensity scores to help design observational studies: application to the tobacco litigation (2001) Health Serv Outcomes Res Methodol, 2 (3), pp. 169-188; Hougaard, M., Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: intravascular ultrasound with iMap: the OCTIVUS trial (2017) Cardiovasc Revascularization Med, 18 (2), pp. 110-117; Kovarnik, T., Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study (2012) Circ J, 76 (1), pp. 176-183; Tsujita, K., Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial (2015) J Am Coll Cardiol, 66 (5), pp. 495-507; Baigent, C., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial (2011) Lancet, 377 (9784), pp. 2181-2192; Wang, D., Fibrates for secondary prevention of cardiovascular disease and stroke (2015) Cochrane Database Syst Rev, (10); Jakob, T., Fibrates for primary prevention of cardiovascular disease events (2016) Cochrane Database Syst Rev, 11; Boden, W.E., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy (2011) N Engl J Med, 365 (24), pp. 2255-2267; Garg, A., Role of niacin in current clinical practice: a systematic review (2017) Am J Med, 130 (2), pp. 173-187; The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease (1984) Jama, 251 (3), pp. 351-364; Watts, G.F., Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) (1992) Lancet, 339 (8793), pp. 563-569; Brensike, J.F., Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study (1984) Circulation, 69 (2), pp. 313-324; Criqui, M.H., Calcium density of coronary artery plaque and risk of incident cardiovascular events (2014) Jama, 311 (3), pp. 271-278; Inoue, K., Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention (2010) JACC Cardiovasc Imaging, 3 (7), pp. 691-698; Motoyama, S., Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome (2009) J Am Coll Cardiol, 54 (1), pp. 49-57; Motoyama, S., Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes (2007) J Am Coll Cardiol, 50 (4), pp. 319-326; Nicholls, S.J., Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial (2016) Jama, 316 (22), pp. 2373-2384",
year = "2019",
doi = "10.1016/j.jcct.2019.01.015",
language = "English",
volume = "13",
pages = "99--104",
journal = "J. Cardiovasc. Comput. Tomogr.",
issn = "1934-5925",
publisher = "Elsevier Inc.",
number = "2",
}